A randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infection
Saye Khoo(University of Liverpool), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Amanda Buadi(University Hospital Southampton NHS Foundation Trust), Richard J. Fitzgerald(University of Limerick), Josh Northey(University Hospital Southampton NHS Foundation Trust), Thomas Jaki(MRC Biostatistics Unit), Abigail Burdon(University of Cambridge), Victoria Shaw(University of Liverpool), Shazaad Ahmad(Newcastle upon Tyne Hospitals NHS Foundation Trust), Helen Reynolds(University of Liverpool), Andrew Owen(University of Liverpool), Laura Dickinson(University of Liverpool), David G. Lalloo(Liverpool School of Tropical Medicine), Michael R. Jacobs(University Hospitals of Cleveland), Emma Knox(University of Southampton), L. Walker(University of Liverpool), Pavel Mozgunov(University of Cambridge), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Katie Bullock(University of Liverpool), Jennifer Gibney(Royal Liverpool and Broadgreen University Hospital NHS Trust), Michelle Tetlow(University of Liverpool), Laura Else(University of Liverpool), Colin Hale(Royal Liverpool and Broadgreen University Hospital NHS Trust), Ján Dixon(University of Sheffield), Rebecca Lyon(Royal Liverpool and Broadgreen University Hospital NHS Trust), Geoffrey Saunders(University of Southampton), Justin Chiong(University of Liverpool), Alieu Amara(University of Liverpool), Calley Middleton(University of Southampton), William Greenhalf(University of Liverpool)
Cited by 1
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k